TY - JOUR AU - Wolchok, J. D. AU - Kluger, H. AU - Callahan, M. K. AU - Postow, M. A. AU - Rizvi, N. A. AU - Lesokhin, A. M. PY - 2013 DA - 2013// TI - Nivolumab plus ipilimumab in advanced melanoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1302369 DO - 10.1056/NEJMoa1302369 ID - Wolchok2013 ER - TY - JOUR AU - Linsley, P. S. AU - Brady, W. AU - Grosmaire, L. AU - Aruffo, A. AU - Damle, N. K. AU - Ledbetter, J. A. PY - 1991 DA - 1991// TI - Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation JO - J Exp Med VL - 173 UR - https://doi.org/10.1084/jem.173.3.721 DO - 10.1084/jem.173.3.721 ID - Linsley1991 ER - TY - JOUR AU - Robert, C. AU - Thomas, L. AU - Bondarenko, I. AU - O’Day, S. AU - Weber, J. AU - Garbe, C. PY - 2011 DA - 2011// TI - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1104621 DO - 10.1056/NEJMoa1104621 ID - Robert2011 ER - TY - JOUR AU - Butte, M. J. AU - Keir, M. E. AU - Phamduy, T. B. AU - Sharpe, A. H. AU - Freeman, G. J. PY - 2007 DA - 2007// TI - Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses JO - Immunity VL - 27 UR - https://doi.org/10.1016/j.immuni.2007.05.016 DO - 10.1016/j.immuni.2007.05.016 ID - Butte2007 ER - TY - JOUR AU - Freeman, G. J. AU - Long, A. J. AU - Iwai, Y. AU - Bourque, K. AU - Chernova, T. AU - Nishimura, H. PY - 2000 DA - 2000// TI - Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.7.1027 DO - 10.1084/jem.192.7.1027 ID - Freeman2000 ER - TY - JOUR AU - Okazaki, T. AU - Honjo, T. PY - 2007 DA - 2007// TI - PD-1 and PD-1 ligands: from discovery to clinical application JO - Int Immunol VL - 19 UR - https://doi.org/10.1093/intimm/dxm057 DO - 10.1093/intimm/dxm057 ID - Okazaki2007 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature. VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Morton, J. J. AU - Bird, G. AU - Keysar, S. B. AU - Astling, D. P. AU - Lyons, T. R. AU - Anderson, R. T. PY - 2016 DA - 2016// TI - XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer JO - Oncogene. VL - 35 UR - https://doi.org/10.1038/onc.2015.94 DO - 10.1038/onc.2015.94 ID - Morton2016 ER - TY - JOUR AU - Morton, J. J. AU - Bird, G. AU - Refaeli, Y. AU - Jimeno, A. PY - 2016 DA - 2016// TI - Humanized mouse xenograft models: narrowing the tumor-microenvironment gap JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-1260 DO - 10.1158/0008-5472.CAN-16-1260 ID - Morton2016 ER - TY - JOUR AU - Landis, M. D. AU - Lehmann, B. D. AU - Pietenpol, J. A. AU - Chang, J. C. PY - 2013 DA - 2013// TI - Patient-derived breast tumor xenografts facilitating personalized cancer therapy JO - Breast Cancer Res VL - 15 UR - https://doi.org/10.1186/bcr3355 DO - 10.1186/bcr3355 ID - Landis2013 ER - TY - JOUR AU - Zhang, X. AU - Claerhout, S. AU - Prat, A. AU - Dobrolecki, L. E. AU - Petrovic, I. AU - Lai, Q. PY - 2013 DA - 2013// TI - A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-4081 DO - 10.1158/0008-5472.CAN-12-4081 ID - Zhang2013 ER - TY - JOUR AU - DeRose, Y. S. AU - Wang, G. AU - Lin, Y. C. AU - Bernard, P. S. AU - Buys, S. S. AU - Ebbert, M. T. PY - 2011 DA - 2011// TI - Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes JO - Nat Med. VL - 17 UR - https://doi.org/10.1038/nm.2454 DO - 10.1038/nm.2454 ID - DeRose2011 ER - TY - JOUR AU - Ding, L. AU - Ellis, M. J. AU - Li, S. AU - Larson, D. E. AU - Chen, K. AU - Wallis, J. W. PY - 2010 DA - 2010// TI - Genome remodelling in a basal-like breast cancer metastasis and xenograft JO - Nature. VL - 464 UR - https://doi.org/10.1038/nature08989 DO - 10.1038/nature08989 ID - Ding2010 ER - TY - JOUR AU - Gao, H. AU - Korn, J. M. AU - Ferretti, S. AU - Monahan, J. E. AU - Wang, Y. AU - Singh, M. PY - 2015 DA - 2015// TI - High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response JO - Nat Med. VL - 21 UR - https://doi.org/10.1038/nm.3954 DO - 10.1038/nm.3954 ID - Gao2015 ER - TY - JOUR AU - Marangoni, E. AU - Vincent-Salomon, A. AU - Auger, N. AU - Degeorges, A. AU - Assayag, F. AU - de Cremoux, P. PY - 2007 DA - 2007// TI - A new model of patient tumor-derived breast cancer xenografts for preclinical assays JO - Clin Cancer Res. VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0078 DO - 10.1158/1078-0432.CCR-07-0078 ID - Marangoni2007 ER - TY - JOUR AU - Townsend, E. C. AU - Murakami, M. A. AU - Christodoulou, A. AU - Christie, A. L. AU - Koster, J. AU - DeSouza, T. A. PY - 2016 DA - 2016// TI - The public repository of xenografts enables discovery and randomized phase II-like trials in mice JO - Cancer Cell VL - 29 UR - https://doi.org/10.1016/j.ccell.2016.03.008 DO - 10.1016/j.ccell.2016.03.008 ID - Townsend2016 ER - TY - JOUR AU - Visonneau, S. AU - Cesano, A. AU - Torosian, M. H. AU - Miller, E. J. AU - Santoli, D. PY - 1998 DA - 1998// TI - Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice JO - Am J Pathol. VL - 152 ID - Visonneau1998 ER - TY - JOUR AU - Fiebig, H. H. AU - Maier, A. AU - Burger, A. M. PY - 2004 DA - 2004// TI - Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery JO - Eur J Cancer. VL - 40 UR - https://doi.org/10.1016/j.ejca.2004.01.009 DO - 10.1016/j.ejca.2004.01.009 ID - Fiebig2004 ER - TY - JOUR AU - Hidalgo, M. AU - Amant, F. AU - Biankin, A. V. AU - Budinská, E. AU - Byrne, A. T. AU - Caldas, C. PY - 2014 DA - 2014// TI - Patient-derived xenograft models: an emerging platform for translational cancer research JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0001 DO - 10.1158/2159-8290.CD-14-0001 ID - Hidalgo2014 ER - TY - JOUR AU - Voskoglou-Nomikos, T. AU - Pater, J. L. AU - Seymour, L. PY - 2003 DA - 2003// TI - Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models JO - Clin Cancer Res. VL - 9 ID - Voskoglou-Nomikos2003 ER - TY - JOUR AU - Krepler, C. AU - Sproesser, K. AU - Brafford, P. AU - Beqiri, M. AU - Garman, B. AU - Xiao, M. PY - 2017 DA - 2017// TI - A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma JO - Cell Rep VL - 21 UR - https://doi.org/10.1016/j.celrep.2017.10.021 DO - 10.1016/j.celrep.2017.10.021 ID - Krepler2017 ER - TY - JOUR AU - Bertotti, A. AU - Migliardi, G. AU - Galimi, F. AU - Sassi, F. AU - Torti, D. AU - Isella, C. PY - 2011 DA - 2011// TI - A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer JO - Cancer Discov. VL - 1 UR - https://doi.org/10.1158/2159-8290.CD-11-0109 DO - 10.1158/2159-8290.CD-11-0109 ID - Bertotti2011 ER - TY - JOUR AU - Migliardi, G. AU - Sassi, F. AU - Torti, D. AU - Galimi, F. AU - Zanella, E. R. AU - Buscarino, M. PY - 2012 DA - 2012// TI - Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2683 DO - 10.1158/1078-0432.CCR-11-2683 ID - Migliardi2012 ER - TY - JOUR AU - Lehmann, S. AU - Walther, T. AU - Kempfert, J. AU - Leontyev, S. AU - Bakhtiary, F. AU - Rastan, A. PY - 2011 DA - 2011// TI - Ten-year follow up after prospectively randomized evaluation of stentless versus conventional xenograft aortic valve replacement JO - J Heart Valve Dis. VL - 20 ID - Lehmann2011 ER - TY - JOUR AU - Nielsen, T. O. AU - Parker, J. S. AU - Leung, S. AU - Voduc, D. AU - Ebbert, M. AU - Vickery, T. PY - 2010 DA - 2010// TI - A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer JO - Clin Cancer Res. VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-1282 DO - 10.1158/1078-0432.CCR-10-1282 ID - Nielsen2010 ER - TY - JOUR AU - Schott, A. F. AU - Landis, M. D. AU - Dontu, G. AU - Griffith, K. A. AU - Layman, R. M. AU - Krop, I. PY - 2013 DA - 2013// TI - Preclinical and clinical studies of γ secretase inhibitors with docetaxel on human breast tumors JO - Clin Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-11-3326 DO - 10.1158/1078-0432.CCR-11-3326 ID - Schott2013 ER - TY - JOUR AU - Hasgur, S. AU - Aryee, K. E. AU - Shultz, L. D. AU - Greiner, D. L. AU - Brehm, M. A. PY - 2016 DA - 2016// TI - Generation of immunodeficient mice bearing human immune systems by the engraftment of hematopoietic stem cells JO - Methods Mol Biol VL - 1438 UR - https://doi.org/10.1007/978-1-4939-3661-8_4 DO - 10.1007/978-1-4939-3661-8_4 ID - Hasgur2016 ER - TY - JOUR AU - Pearson, T. AU - Greiner, D. L. AU - Shultz, L. D. PY - 2008 DA - 2008// TI - Creation of “humanized” mice to study human immunity JO - Curr Protoc Immunol VL - Chapter 15 ID - Pearson2008 ER - TY - JOUR AU - Ginestier, C. AU - Hur, M. H. AU - Charafe-Jauffret, E. AU - Monville, F. AU - Dutcher, J. AU - Brown, M. PY - 2007 DA - 2007// TI - ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome JO - Cell Stem Cell VL - 1 UR - https://doi.org/10.1016/j.stem.2007.08.014 DO - 10.1016/j.stem.2007.08.014 ID - Ginestier2007 ER - TY - JOUR AU - Granados-Principal, S. AU - Liu, Y. AU - Guevara, M. L. AU - Blanco, E. AU - Choi, D. S. AU - Qian, W. PY - 2015 DA - 2015// TI - Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer JO - Breast Cancer Res. VL - 17 UR - https://doi.org/10.1186/s13058-015-0527-x DO - 10.1186/s13058-015-0527-x ID - Granados-Principal2015 ER - TY - JOUR AU - Choi, D. S. AU - Blanco, E. AU - Kim, Y. S. AU - Rodriguez, A. A. AU - Zhao, H. AU - Huang, T. H. PY - 2014 DA - 2014// TI - Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1 JO - Stem Cells. VL - 32 UR - https://doi.org/10.1002/stem.1746 DO - 10.1002/stem.1746 ID - Choi2014 ER - TY - JOUR AU - Wang, Q. AU - Li, N. AU - Wang, X. AU - Kim, M. M. AU - Evers, B. M. PY - 2002 DA - 2002// TI - Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line JO - Clin Cancer Res. VL - 8 ID - Wang2002 ER - TY - JOUR AU - Wege, A. K. AU - Schmidt, M. AU - Ueberham, E. AU - Ponnath, M. AU - Ortmann, O. AU - Brockhoff, G. PY - 2014 DA - 2014// TI - Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies JO - MAbs VL - 6 UR - https://doi.org/10.4161/mabs.29111 DO - 10.4161/mabs.29111 ID - Wege2014 ER - TY - JOUR AU - Dunn, G. P. AU - Bruce, A. T. AU - Ikeda, H. AU - Old, L. J. AU - Schreiber, R. D. PY - 2002 DA - 2002// TI - Cancer immunoediting: from immunosurveillance to tumor escape JO - Nat Immunol. VL - 3 UR - https://doi.org/10.1038/ni1102-991 DO - 10.1038/ni1102-991 ID - Dunn2002 ER - TY - JOUR AU - Wang, M. AU - Keck, J. G. AU - Cheng, M. AU - Cai, D. AU - Shultz, L. AU - Palucka, K. PY - 2015 DA - 2015// TI - Abstract LB-050: Patient-derived tumor xenografts in humanized NSG mice: a model to study immune responses in cancer therapy [abstract] JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/1538-7445.AM2015-LB-050 DO - 10.1158/1538-7445.AM2015-LB-050 ID - Wang2015 ER - TY - JOUR AU - Wang, M. AU - Yao, L. C. AU - Cheng, M. AU - Cai, D. AU - Martinek, J. AU - Pan, C. X. PY - 2018 DA - 2018// TI - Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy JO - FASEB J VL - 32 UR - https://doi.org/10.1096/fj.201700740R DO - 10.1096/fj.201700740R ID - Wang2018 ER - TY - JOUR AU - Mischinger, J. AU - Comperat, E. AU - Schwentner, C. AU - Stenzl, A. AU - Gakis, G. PY - 2015 DA - 2015// TI - Inflammation and cancer: what can we therapeutically expect from checkpoint inhibitors? JO - Curr Urol Rep. VL - 16 UR - https://doi.org/10.1007/s11934-015-0532-8 DO - 10.1007/s11934-015-0532-8 ID - Mischinger2015 ER - TY - JOUR AU - Ribas, A. PY - 2015 DA - 2015// TI - Adaptive immune resistance: how cancer protects from immune attack JO - Cancer Discov. VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0563 DO - 10.1158/2159-8290.CD-15-0563 ID - Ribas2015 ER - TY - JOUR AU - Yao, L. -. C. AU - Riess, J. AU - Cheng, M. AU - Wang, M. AU - Banchereau, J. AU - Shultz, L. PY - 2016 DA - 2016// TI - Patient-derived tumor xenografts in humanized NSG-SGM3 mice: a new immuno-oncology platform [abstract] JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.3074 DO - 10.1200/JCO.2016.34.15_suppl.3074 ID - Yao2016 ER - TY - JOUR AU - Carbone, D. P. AU - Reck, M. AU - Paz-Ares, L. AU - Creelan, B. AU - Horn, L. AU - Steins, M. PY - 2017 DA - 2017// TI - First-line Nivolumab in stage IV or recurrent non–small-cell lung cancer JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613493 DO - 10.1056/NEJMoa1613493 ID - Carbone2017 ER - TY - JOUR AU - Festino, L. AU - Botti, G. AU - Lorigan, P. AU - Masucci, G. V. AU - Hipp, J. D. AU - Horak, C. E. PY - 2016 DA - 2016// TI - Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? JO - Drugs. VL - 76 UR - https://doi.org/10.1007/s40265-016-0588-x DO - 10.1007/s40265-016-0588-x ID - Festino2016 ER - TY - JOUR AU - Mori, H. AU - Kubo, M. AU - Yamaguchi, R. AU - Nishimura, R. AU - Osako, T. AU - Arima, N. PY - 2017 DA - 2017// TI - The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer JO - Oncotarget. VL - 8 ID - Mori2017 ER - TY - JOUR AU - Rizvi, N. A. AU - Mazieres, J. AU - Planchard, D. AU - Stinchcombe, T. E. AU - Dy, G. K. AU - Antonia, S. J. PY - 2015 DA - 2015// TI - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70054-9 DO - 10.1016/S1470-2045(15)70054-9 ID - Rizvi2015 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med. VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Mittendorf, E. A. AU - Philips, A. V. AU - Meric-Bernstam, F. AU - Qiao, N. AU - Wu, Y. AU - Harrington, S. PY - 2014 DA - 2014// TI - PD-L1 expression in triple-negative breast cancer JO - Cancer Immunol Res. VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0127 DO - 10.1158/2326-6066.CIR-13-0127 ID - Mittendorf2014 ER - TY - JOUR AU - Nanda, R. AU - Chow, L. Q. M. AU - Dees, E. C. AU - Berger, R. AU - Gupta, S. AU - Geva, R. PY - 2016 DA - 2016// TI - Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study JO - J Clin Oncol. VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8931 DO - 10.1200/JCO.2015.64.8931 ID - Nanda2016 ER - TY - JOUR AU - Nanda, R. AU - Liu, M. C. AU - Yau, C. AU - Asare, S. AU - Hylton, N. AU - van ’t Veer, L. PY - 2017 DA - 2017// TI - Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 [abstract] JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.506 DO - 10.1200/JCO.2017.35.15_suppl.506 ID - Nanda2017 ER - TY - JOUR AU - Schmid, P. AU - Park, Y. H. AU - Muñoz-Couselo, E. AU - Kim, S. -. B. AU - Sohn, J. AU - Im, S. A. PY - 2017 DA - 2017// TI - Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173 [abstract] JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.35.15_suppl.556 DO - 10.1200/JCO.2017.35.15_suppl.556 ID - Schmid2017 ER - TY - JOUR AU - Calabro, L. AU - Danielli, R. AU - Sigalotti, L. AU - Maio, M. PY - 2010 DA - 2010// TI - Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications JO - Semin Oncol VL - 37 UR - https://doi.org/10.1053/j.seminoncol.2010.09.006 DO - 10.1053/j.seminoncol.2010.09.006 ID - Calabro2010 ER - TY - JOUR AU - McArthur, H. L. AU - Diab, A. AU - Page, D. B. AU - Yuan, J. AU - Solomon, S. B. AU - Sacchini, V. PY - 2016 DA - 2016// TI - A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling JO - Clin Cancer Res. VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0190 DO - 10.1158/1078-0432.CCR-16-0190 ID - McArthur2016 ER - TY - JOUR AU - Schoenborn, J. R. AU - Wilson, C. B. PY - 2007 DA - 2007// TI - Regulation of interferon-γ during innate and adaptive immune responses JO - Adv Immunol. VL - 96 UR - https://doi.org/10.1016/S0065-2776(07)96002-2 DO - 10.1016/S0065-2776(07)96002-2 ID - Schoenborn2007 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in Advanced Melanoma JO - N Engl J Med. VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Luen, S. J. AU - Savas, P. AU - Fox, S. B. AU - Salgado, R. AU - Loi, S. PY - 2017 DA - 2017// TI - Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer JO - Pathology. VL - 49 UR - https://doi.org/10.1016/j.pathol.2016.10.010 DO - 10.1016/j.pathol.2016.10.010 ID - Luen2017 ER - TY - JOUR AU - Bedognetti, D. AU - Maccalli, C. AU - Bader, S. B. AU - Marincola, F. M. AU - Seliger, B. PY - 2016 DA - 2016// TI - Checkpoint inhibitors and their application in breast cancer JO - Breast Care (Basel). VL - 11 UR - https://doi.org/10.1159/000445335 DO - 10.1159/000445335 ID - Bedognetti2016 ER - TY - JOUR AU - Emens, L. A. PY - 2018 DA - 2018// TI - Breast cancer immunotherapy: facts and hopes JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-16-3001 DO - 10.1158/1078-0432.CCR-16-3001 ID - Emens2018 ER - TY - JOUR AU - Ancevski Hunter, K. AU - Socinski, M. A. AU - Villaruz, L. C. PY - 2018 DA - 2018// TI - PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer JO - Mol Diagn Ther VL - 22 UR - https://doi.org/10.1007/s40291-017-0308-6 DO - 10.1007/s40291-017-0308-6 ID - Ancevski Hunter2018 ER - TY - JOUR AU - Voong, K. R. AU - Feliciano, J. AU - Becker, D. AU - Levy, B. PY - 2017 DA - 2017// TI - Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer JO - Ann Transl Med. VL - 5 UR - https://doi.org/10.21037/atm.2017.06.48 DO - 10.21037/atm.2017.06.48 ID - Voong2017 ER - TY - JOUR AU - Yaziji, H. AU - Taylor, C. R. PY - 2017 DA - 2017// TI - PD-L1 assessment for targeted therapy testing in cancer: urgent need for realistic economic and practice expectations JO - Appl Immunohistochem Mol Morphol. VL - 25 UR - https://doi.org/10.1097/PAI.0000000000000472 DO - 10.1097/PAI.0000000000000472 ID - Yaziji2017 ER - TY - JOUR AU - Li, X. AU - Wetherilt, C. S. AU - Krishnamurti, U. AU - Yang, J. AU - Ma, Y. AU - Styblo, T. M. PY - 2016 DA - 2016// TI - Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer JO - Am J Clin Pathol. VL - 146 UR - https://doi.org/10.1093/ajcp/aqw134 DO - 10.1093/ajcp/aqw134 ID - Li2016 ER - TY - JOUR AU - Botti, G. AU - Collina, F. AU - Scognamiglio, G. AU - Rao, F. AU - Peluso, V. AU - De Cecio, R. PY - 2017 DA - 2017// TI - Programmed death ligand 1 (PD-L1) tumor expression is associated with a better prognosis and diabetic disease in triple negative breast cancer patients JO - Int J Mol Sci VL - 18 UR - https://doi.org/10.3390/ijms18020459 DO - 10.3390/ijms18020459 ID - Botti2017 ER - TY - JOUR AU - Emens, L. A. AU - Braiteh, F. S. AU - Cassier, P. AU - Delord, J. -. P. AU - Eder, J. P. AU - Fasso, M. PY - 2015 DA - 2015// TI - Abstract 2859: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [abstract] JO - Cancer Res. VL - 75 UR - https://doi.org/10.1158/1538-7445.AM2015-2859 DO - 10.1158/1538-7445.AM2015-2859 ID - Emens2015 ER - TY - JOUR AU - Mehnert, J. M. AU - Monjazeb, A. M. AU - Beerthuijzen, J. M. T. AU - Collyar, D. AU - Rubinstein, L. AU - Harris, L. N. PY - 2017 DA - 2017// TI - The challenge for development of valuable immuno-oncology biomarkers JO - Clin Cancer Res. VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3063 DO - 10.1158/1078-0432.CCR-16-3063 ID - Mehnert2017 ER - TY - JOUR AU - Salgado, R. AU - Denkert, C. AU - Demaria, S. AU - Sirtaine, N. AU - Klauschen, F. AU - Pruneri, G. PY - 2015 DA - 2015// TI - The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014 JO - Ann Oncol. VL - 26 UR - https://doi.org/10.1093/annonc/mdu450 DO - 10.1093/annonc/mdu450 ID - Salgado2015 ER - TY - JOUR AU - Savas, P. AU - Salgado, R. AU - Denkert, C. AU - Sotiriou, C. AU - Darcy, P. K. AU - Smyth, M. J. PY - 2016 DA - 2016// TI - Clinical relevance of host immunity in breast cancer: from TILs to the clinic JO - Nat Rev Clin Oncol. VL - 13 UR - https://doi.org/10.1038/nrclinonc.2015.215 DO - 10.1038/nrclinonc.2015.215 ID - Savas2016 ER - TY - JOUR AU - Vonderheide, R. H. AU - LoRusso, P. M. AU - Khalil, M. AU - Gartner, E. M. AU - Khaira, D. AU - Soulieres, D. PY - 2010 DA - 2010// TI - Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells JO - Clin Cancer Res. VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-0505 DO - 10.1158/1078-0432.CCR-10-0505 ID - Vonderheide2010 ER - TY - JOUR AU - Ribas, A. AU - Kefford, R. AU - Marshall, M. A. AU - Punt, C. J. AU - Haanen, J. B. AU - Marmol, M. PY - 2013 DA - 2013// TI - Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma JO - J Clin Oncol. VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.6112 DO - 10.1200/JCO.2012.44.6112 ID - Ribas2013 ER - TY - JOUR AU - Loi, S. AU - Michiels, S. AU - Salgado, R. AU - Sirtaine, N. AU - Jose, V. AU - Fumagalli, D. PY - 2014 DA - 2014// TI - Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial JO - Ann Oncol. VL - 25 UR - https://doi.org/10.1093/annonc/mdu112 DO - 10.1093/annonc/mdu112 ID - Loi2014 ER - TY - JOUR AU - Schumacher, T. N. AU - Schreiber, R. D. PY - 2015 DA - 2015// TI - Neoantigens in cancer immunotherapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa4971 DO - 10.1126/science.aaa4971 ID - Schumacher2015 ER - TY - JOUR AU - Chen, L. AU - Han, X. PY - 2015 DA - 2015// TI - Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future JO - J Clin Invest. VL - 125 UR - https://doi.org/10.1172/JCI80011 DO - 10.1172/JCI80011 ID - Chen2015 ER - TY - JOUR AU - Shi, Y. AU - Liu, C. H. AU - Roberts, A. I. AU - Das, J. AU - Xu, G. AU - Ren, G. PY - 2006 DA - 2006// TI - Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know JO - Cell Res. VL - 16 UR - https://doi.org/10.1038/sj.cr.7310017 DO - 10.1038/sj.cr.7310017 ID - Shi2006 ER - TY - JOUR AU - Byrne, A. T. AU - Alferez, D. G. AU - Amant, F. AU - Annibali, D. AU - Arribas, J. AU - Biankin, A. V. PY - 2017 DA - 2017// TI - Interrogating open issues in cancer precision medicine with patient-derived xenografts JO - Nat Rev Cancer. VL - 17 UR - https://doi.org/10.1038/nrc.2016.140 DO - 10.1038/nrc.2016.140 ID - Byrne2017 ER -